MedTrace Logo

Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation

NCT04368442 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 583

Last updated 2020-04-29

No results posted yet for this study

Summary

The purpose of this study is to investigate the prevalence germline pathogenic BRCA1/2 mutation in a large group of potential candidate of PARP inhibitors, among the unselected patients with HER2-negative unresectable locally advanced or metastatic breast cancer.

Conditions

  • Breast Cancer Metastatic

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • YEON HEE PARK · Samsung Medical Center

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-17
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04368442 on ClinicalTrials.gov